ATE524433T1 - Trpv1 agonisten , zubereitungen die diese enthalten und ihre anwendung - Google Patents

Trpv1 agonisten , zubereitungen die diese enthalten und ihre anwendung

Info

Publication number
ATE524433T1
ATE524433T1 AT05770295T AT05770295T ATE524433T1 AT E524433 T1 ATE524433 T1 AT E524433T1 AT 05770295 T AT05770295 T AT 05770295T AT 05770295 T AT05770295 T AT 05770295T AT E524433 T1 ATE524433 T1 AT E524433T1
Authority
AT
Austria
Prior art keywords
sub
preparations containing
trpv1 agonists
hydrogen
trpv1
Prior art date
Application number
AT05770295T
Other languages
English (en)
Inventor
Paolo Morazzoni
Antonella Riva
Gabriele Fontana
Giovanni Appendino
Marzo Vincenzo Di
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Application granted granted Critical
Publication of ATE524433T1 publication Critical patent/ATE524433T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42Separation; Purification; Stabilisation; Use of additives
    • C07C303/44Separation; Purification
    • C07C303/46Separation; Purification from by-products of refining mineral oils with sulfuric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/38Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/46Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
AT05770295T 2004-07-30 2005-07-06 Trpv1 agonisten , zubereitungen die diese enthalten und ihre anwendung ATE524433T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001566A ITMI20041566A1 (it) 2004-07-30 2004-07-30 "trpv1 agonisti, formulazioni che li contengono e loro usi"
PCT/EP2005/007292 WO2006010445A1 (en) 2004-07-30 2005-07-06 Trpv1 agonists, formulations containing them and uses thereof

Publications (1)

Publication Number Publication Date
ATE524433T1 true ATE524433T1 (de) 2011-09-15

Family

ID=34979120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05770295T ATE524433T1 (de) 2004-07-30 2005-07-06 Trpv1 agonisten , zubereitungen die diese enthalten und ihre anwendung

Country Status (19)

Country Link
US (1) US7429673B2 (de)
EP (1) EP1773757B1 (de)
JP (1) JP4819810B2 (de)
KR (1) KR101206571B1 (de)
CN (1) CN101006047B (de)
AT (1) ATE524433T1 (de)
AU (1) AU2005266684B2 (de)
CA (1) CA2575341C (de)
DK (1) DK1773757T3 (de)
ES (1) ES2370029T3 (de)
HK (1) HK1105947A1 (de)
IL (1) IL181024A (de)
IT (1) ITMI20041566A1 (de)
NO (1) NO338341B1 (de)
PL (1) PL1773757T3 (de)
PT (1) PT1773757E (de)
RU (1) RU2379282C2 (de)
SI (1) SI1773757T1 (de)
WO (1) WO2006010445A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
KR101034300B1 (ko) * 2008-12-02 2011-05-16 고려대학교 산학협력단 Trpv3 활성 억제 약물 및 이의 활용
KR101034299B1 (ko) * 2008-12-02 2011-05-16 고려대학교 산학협력단 Trpv3 활성 조절 약물 및 이의 활용
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CA3027255C (en) 2009-07-10 2022-06-21 The General Hospital Corporation Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (de) 2010-02-02 2014-10-15 Novartis AG Cyclohexylamidderivate als crf-rezeptorantagonisten
US10327467B2 (en) 2010-04-14 2019-06-25 Altria Client Services Llc Preformed smokeless tobacco product
HUE035134T2 (en) 2010-07-27 2018-05-02 Flex Pharma Inc Methods and compositions for preventing and relieving muscle cramps and recovering from post-exercise neuromuscular excitability and fatigue
US10799548B2 (en) * 2013-03-15 2020-10-13 Altria Client Services Llc Modifying taste and sensory irritation of smokeless tobacco and non-tobacco products
RU2018107695A (ru) 2015-08-03 2019-09-05 Президент Энд Феллоуз Оф Гарвард Колледж Заряженные блокаторы ионных каналов и способы их применения
WO2018136943A1 (en) 2017-01-23 2018-07-26 Flex Pharma, Inc. Compositions and methods affecting exercise performance
MA55311A (fr) 2019-03-11 2022-01-19 Nocion Therapeutics Inc Bloqueurs de canaux ioniques chargés et procédés d'utilisation
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
KR20210143791A (ko) 2019-03-11 2021-11-29 녹시온 테라퓨틱스 인코포레이티드 하전된 이온 채널 차단제 및 사용 방법
KR20210145164A (ko) 2019-03-11 2021-12-01 녹시온 테라퓨틱스 인코포레이티드 에스테르 치환된 이온 채널 차단제 및 사용 방법
CN114828845A (zh) 2019-11-06 2022-07-29 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP4118070A4 (de) 2020-03-11 2024-04-10 Nocion Therapeutics Inc Geladene ionenkanalblocker und verfahren zur verwendung
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493848A (en) * 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
FR2619810B1 (fr) * 1987-09-02 1990-01-05 Hoechst France Nouveaux monomeres ethyleniques polyfonctionnels
IT1302264B1 (it) * 1998-09-24 2000-09-05 Innovet Italia Srl Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi
JP2004182674A (ja) * 2002-12-05 2004-07-02 Kureha Chem Ind Co Ltd バニリル脂肪酸アミドを含む抗腫瘍医薬組成物

Also Published As

Publication number Publication date
NO20070531L (no) 2007-04-30
IL181024A0 (en) 2007-07-04
RU2007103344A (ru) 2008-08-10
AU2005266684B2 (en) 2012-05-10
US20080132573A1 (en) 2008-06-05
HK1105947A1 (en) 2008-02-29
NO338341B1 (no) 2016-08-08
CN101006047B (zh) 2010-08-11
JP4819810B2 (ja) 2011-11-24
ES2370029T3 (es) 2011-12-12
AU2005266684A1 (en) 2006-02-02
RU2379282C2 (ru) 2010-01-20
JP2008508202A (ja) 2008-03-21
CN101006047A (zh) 2007-07-25
EP1773757A1 (de) 2007-04-18
KR101206571B1 (ko) 2012-11-29
PT1773757E (pt) 2011-10-27
PL1773757T3 (pl) 2012-02-29
IL181024A (en) 2011-12-29
ITMI20041566A1 (it) 2004-10-30
KR20070039078A (ko) 2007-04-11
WO2006010445A1 (en) 2006-02-02
EP1773757B1 (de) 2011-09-14
US7429673B2 (en) 2008-09-30
CA2575341A1 (en) 2006-02-02
DK1773757T3 (da) 2011-11-21
SI1773757T1 (sl) 2011-12-30
CA2575341C (en) 2014-09-23

Similar Documents

Publication Publication Date Title
ATE524433T1 (de) Trpv1 agonisten , zubereitungen die diese enthalten und ihre anwendung
RS39704A (sr) Novi 1,2,4-tiadiazolijum derivati kao modulatori melanokortinskog receptora
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
TNSN02012A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
MX2007008308A (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-.
ATE433447T1 (de) Pyrimiidinverbindungen
TW200732339A (en) Nitrogen-containing bicyclic heteroaryl compounds and methods of use
HUP0302960A2 (hu) Kemokinreceptorhoz kötődő heterociklusos vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20050065L (no) Kjemiske forbindelser
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
MA27930A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
ATE445617T1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
GB0512284D0 (en) Organic compounds
DE602006010702D1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
HUP0201302A2 (hu) IL-8 receptor antagonista ciklusos guanidinszármazékok
SE0403118D0 (sv) New compounds 2
SE0403117D0 (sv) New compounds 1
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
ATE340175T1 (de) Imidazo(4,5-böchinolinderivate und ihre verwendung als inhibitoren der induzierbaren no- synthase
TH87428B (th) สารประกอบชนิดใหม่

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1773757

Country of ref document: EP